22
ALL19
GC Biopharma3
GC CellYear
22
ALL12
20248
20232
2022DEALS // DEV.
22
ALL9
Deals13
DevelopmentsCountry
21
ALL1
INDIA17
SOUTH KOREA3
U.S.A22
ALL1
Catalyst Biosciences1
EuBiologics1
Hanmi Pharmaceutical1
Immetas Therapeutics1
KabaFusion9
Not Applicable3
Novel Pharma2
Novelty Nobility1
PT Bifarma1
Rivaara Labs1
Soleo HealthTherapeutic Area
22
ALL4
Genetic Disease3
Immunology3
Infections and Infectious Diseases2
Oncology1
Pulmonary/Respiratory Diseases1
Rare Diseases and Disorders8
TechnologyStudy Phase
22
ALL13
Approved2
Phase III1
Phase II1
Phase I/ Phase II2
IND Enabling2
Preclinical1
DiscoveryDeal Type
9
ALL1
Acquisition3
Agreement1
Collaboration2
Licensing Agreement2
PartnershipProduct Type
22
ALL3
Cell and Gene therapy15
Large molecule4
VaccineDosage Form
8
ALL3
Infusion2
Injectable/Injection1
Injection1
Intravenous1
LiquidLead Product
22
ALL1
AB-2011
ADC-based Therapy1
Antibody-based Therapy1
Autologous T-cell Immunotherapy1
CIK-based Cell Therapy1
Euvichol1
GC11091
GC1126A1
Human Immune Globulin3
Immune Globulin Intravenous, Human1
Immune Globulin Intravenous, Human-stwk1
MG11111
Marzeptacog Alfa1
Quadrivalent Influenza Vaccine4
Recombinant Human Heparan N-sulfatase1
alpha-galactosidase A1
mRNA TherapeuticTarget
0
ALLLead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Novel Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
GC Biopharma Begins Global Phase I MPS IIIA Treatment Trial with First Dosed
Details : GC1130A' is a first-in-class treatment high-quality recombinant protein that is administered via ICV injection to bypass the BBB for the treatment of MPS IIIA.
Brand Name : GC1130A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 25, 2024
Lead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Novel Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
GC Biopharma, Novelty Nobility Partner on Geographic Atrophy R&D
Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Recipient : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
GC Biopharma And Novelty Nobility Team Up for Geographic Atrophy R&D
Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Recipient : Novelty Nobility
Deal Size : Undisclosed
Deal Type : Agreement
GC Cell and PT Bifarma Sign Licensing Deal For Immuncell-LC in Indonesia
Details : Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC, an anti-cancer immune cell therapy, for 15 years.
Brand Name : Immuncell-LC
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GC Biopharma Launches ALYGLO™ for Primary Humoral Immunodeficiency in the U.S.
Details : ALYGLO (immune globulin intravenous, human-stwk) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults.
Brand Name : Alyglo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 09, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : alpha-galactosidase A
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Hanmi Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
GC Biopharma and Hanmi Receive IND Clearance for Phase 1/2 Trial in the US
Details : GC1134A/HM15421 is a long-acting alpha-galactosidase that can be administered subcutaneously once a month in patients with fabry disease, also to improve patient's convenience.
Brand Name : GC1134A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2024
Lead Product(s) : alpha-galactosidase A
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Hanmi Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : KabaFusion
Deal Size : Undisclosed
Deal Type : Partnership
KabaFusion Selected by GC Biopharma USA as Limited Distribution Partner for ALYGLO™
Details : GC Biopharma partners with KabaFusion for the distribution to provide Alyglo (Immune Globulin Intravenous, Human) for treating primary humoral immunodeficiency for Adults, 17 years and older.
Brand Name : Alyglo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : KabaFusion
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Soleo Health
Deal Size : Undisclosed
Deal Type : Partnership
Soleo Health Selected as Specialty Pharmacy for ALYGLO™ for Adults with PI
Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.
Brand Name : Alyglo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Soleo Health
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A
Details : GC1130A (recombinant human heparan N-sulfatase) is an intracerebroventricular enzyme replacement therapy candidate. It is being evaluated for the treatment of sanfilippo syndrome type A.
Brand Name : GC1130A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 10, 2024
Lead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Novel Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
Details : GC1130A (recombinant human heparan N-sulfatase), is an intracerebroventricular (ICV) enzyme replacement therapy candidate under investigation for the treatment of sanfilippo syndrome.
Brand Name : GC1130A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 20, 2024
Lead Product(s) : Recombinant Human Heparan N-sulfatase
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Novel Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?